← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Insmed Incorporated (INSM) 10-Year Financial Performance & Capital Metrics

INSM • • Industrial / General
HealthcarePharmaceuticalsBiopharmaceutical R&DRare Disease Therapeutics
AboutInsmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.Show more
  • Revenue $364M +19.2%
  • EBITDA -$867M -24.1%
  • Net Income -$914M -21.9%
  • EPS (Diluted) -5.57 -4.3%
  • Gross Margin 76.43% -2.7%
  • EBITDA Margin -238.44% -4.1%
  • Operating Margin -241.47% -3.9%
  • Net Margin -251.24% -2.3%
  • ROE -320.2%
  • ROIC -91.86% +49.8%
  • Debt/Equity 4.60
  • Interest Coverage -10.34 -19.1%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Momentum leader: RS Rating 85 (top 15%)
  • ✓Strong 5Y sales CAGR of 21.7%

✗Weaknesses

  • ✗High debt to equity ratio of 4.6x
  • ✗Weak Piotroski F-Score: 3/9
  • ✗Negative free cash flow
  • ✗Shares diluted 16.8% in last year
  • ✗Expensive at 91.6x book value
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y41.26%
5Y21.66%
3Y24.5%
TTM30.34%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM-36.97%

EPS CAGR

10Y-
5Y-
3Y-
TTM-11.53%

ROCE

10Y Avg-50.66%
5Y Avg-46.91%
3Y Avg-50.92%
Latest-62.03%

Peer Comparison

Rare Disease Therapeutics
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
INSMInsmed Incorporated33.97B159.27-28.5919.17%-264.83%-125.2%4.60

Profit & Loss

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+0009.84M136.47M164.41M188.46M245.36M305.21M363.71M
Revenue Growth %-1%---12.88%0.2%0.15%0.3%0.24%0.19%
Cost of Goods Sold+1.98M2.44M2.9M2.42M24.21M39.87M44.15M55.13M65.57M85.74M
COGS % of Revenue---0.25%0.18%0.24%0.23%0.22%0.21%0.24%
Gross Profit+-1.98M-2.44M-2.9M7.41M112.25M124.54M144.31M190.23M239.63M277.96M
Gross Margin %---0.75%0.82%0.76%0.77%0.78%0.79%0.76%
Gross Profit Growth %0.91%-0.23%-0.19%3.55%14.15%0.11%0.16%0.32%0.26%0.16%
Operating Expenses+117.49M173.4M188.92M314.75M347.5M389.77M519.4M647.55M949.26M1.16B
OpEx % of Revenue---32%2.55%2.37%2.76%2.64%3.11%3.18%
Selling, General & Admin43.22M50.68M79.17M168.22M210.8M203.61M234.27M265.78M344.5M461.12M
SG&A % of Revenue---17.1%1.54%1.24%1.24%1.08%1.13%1.27%
Research & Development74.28M122.72M109.75M145.28M131.71M181.16M272.74M397.52M571.01M598.37M
R&D % of Revenue---14.77%0.97%1.1%1.45%1.62%1.87%1.65%
Other Operating Expenses-33K119K300K1.25M4.99M5M12.39M-15.75M33.75M96.73M
Operating Income+-117.49M-173.4M-188.92M-307.34M-235.25M-265.23M-375.09M-457.32M-709.63M-878.25M
Operating Margin %----31.25%-1.72%-1.61%-1.99%-1.86%-2.33%-2.41%
Operating Income Growth %-0.34%-0.48%-0.09%-0.63%0.23%-0.13%-0.41%-0.22%-0.55%-0.24%
EBITDA+-115.51M-170.96M-186.02M-302.51M-225.06M-251.08M-360.91M-446.99M-699.05M-867.24M
EBITDA Margin %----30.76%-1.65%-1.53%-1.92%-1.82%-2.29%-2.38%
EBITDA Growth %-0.34%-0.48%-0.09%-0.63%0.26%-0.12%-0.44%-0.24%-0.56%-0.24%
D&A (Non-Cash Add-back)1.98M2.44M2.9M4.83M10.18M14.15M14.18M10.33M10.58M11.01M
EBIT-117.27M-172.68M-187M-300M-227.25M-264.52M-397.83M-457.7M-670.76M-829.81M
Net Interest Income+-2.63M-2.89M-4.3M-15.13M-17.78M-27.86M-40.3M-15.37M-39.56M-31.61M
Interest Income261K604K1.62M10.34M9.92M1.7M174K11.08M42.13M53.31M
Interest Expense2.89M3.5M5.92M25.47M27.7M29.56M40.47M26.45M81.69M84.91M
Other Income/Expense-2.66M-2.77M-4M-16.74M-18.32M-27.46M-61.32M-22.83M-37.39M-31.81M
Pretax Income+-120.15M-176.18M-192.92M-324.08M-253.56M-292.69M-436.41M-480.15M-747.01M-910.07M
Pretax Margin %----32.95%-1.86%-1.78%-2.32%-1.96%-2.45%-2.5%
Income Tax+-1.97M98K-272K201K777K1.4M-1.76M1.38M2.56M3.71M
Effective Tax Rate %0.98%1%1%1%1%1%1%1%1%1%
Net Income+-118.18M-176.27M-192.65M-324.28M-254.34M-294.09M-434.65M-481.53M-749.57M-913.77M
Net Margin %----32.97%-1.86%-1.79%-2.31%-1.96%-2.46%-2.51%
Net Income Growth %-0.49%-0.49%-0.09%-0.68%0.22%-0.16%-0.48%-0.11%-0.56%-0.22%
Net Income (Continuing)-118.18M-176.27M-192.65M-324.28M-254.34M-294.09M-434.65M-481.53M-749.57M-913.77M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)+-2.02-2.85-2.89-4.22-3.01-3.01-3.88-3.91-5.34-5.57
EPS Growth %-0.1%-0.41%-0.01%-0.46%0.29%0%-0.29%-0.01%-0.37%-0.04%
EPS (Basic)-2.02-2.85-2.89-4.22-3.01-3.01-3.88-3.91-5.34-5.57
Diluted Shares Outstanding58.63M61.89M66.58M76.89M84.56M97.61M112.11M123.03M140.43M164.04M
Basic Shares Outstanding58.51M61.85M66.58M76.84M84.56M97.61M112.11M123.03M140.43M164.04M
Dividend Payout Ratio----------

Balance Sheet

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+288.12M168.41M389.44M518.95M555.19M622.89M837.04M1.27B929.06M1.62B
Cash & Short-Term Investments282.88M162.59M381.17M495.07M487.43M532.76M716.78M1.15B780.45M1.43B
Cash Only282.88M162.59M381.17M495.07M487.43M532.76M716.78M1.07B482.37M555.03M
Short-Term Investments000000074.24M298.07M878.8M
Accounts Receivable0005.51M19.23M16.56M24.35M29.71M41.19M52.01M
Days Sales Outstanding---204.6751.4436.7747.1644.249.2652.2
Inventory0007.03M28.31M49.59M67.01M69.92M83.25M98.58M
Days Inventory Outstanding---1.06K426.82453.98553.96462.97463.38419.64
Other Current Assets000000025.47M24.18M37.24M
Total Non-Current Assets+68.44M69.55M72.6M85.61M187.1M173.26M406.47M383.05M400.77M403.57M
Property, Plant & Equipment8.09M10.02M12.43M22.64M113.11M97.23M95.52M102.08M104.39M115.58M
Fixed Asset Turnover---0.43x1.21x1.69x1.97x2.40x2.92x3.15x
Goodwill000000136.11M136.11M136.11M136.11M
Intangible Assets58.2M58.2M58.2M58.67M53.68M49.26M73.81M68.76M63.7M58.65M
Long-Term Investments00000050.04M000
Other Non-Current Assets2.15M1.33M1.97M4.3M20.31M26.77M50.99M76.1M96.57M93.23M
Total Assets+356.56M237.96M462.05M604.56M742.3M796.15M1.24B1.66B1.33B2.03B
Asset Turnover---0.02x0.18x0.21x0.15x0.15x0.23x0.18x
Asset Growth %0.54%-0.33%0.94%0.31%0.23%0.07%0.56%0.33%-0.2%0.52%
Total Current Liabilities+22.26M27.99M44.66M79.73M85.24M118.81M135.17M190.24M225.63M297.53M
Accounts Payable7.47M10.44M14.67M17.74M13.18M42.85M35.78M50.46M65.39M73.03M
Days Payables Outstanding1.38K1.56K1.85K2.67K198.75392.29295.82334.11364310.9
Short-Term Debt3.11M0000000016.5M
Deferred Revenue (Current)0000000000
Other Current Liabilities4.99M7.67M12.84M23.74M19.42M25.59M33.46M42.74M55.63M127.69M
Current Ratio12.94x6.02x8.72x6.51x6.51x5.24x6.19x6.69x4.12x5.45x
Quick Ratio12.94x6.02x8.72x6.42x6.18x4.83x5.70x6.33x3.75x5.12x
Cash Conversion Cycle----1.41K279.5198.46305.3173.06148.64160.94
Total Non-Current Liabilities+22.6M55.48M56.33M316.56M395.38M401.46M697.87M1.38B1.44B1.44B
Long-Term Debt22.03M54.79M55.57M316.56M335.94M356.32M566.59M1.13B1.16B1.26B
Capital Lease Obligations000048.84M35.97M35.54M44.49M38.04M33.18M
Deferred Tax Liabilities0000000000
Other Non-Current Liabilities572K693K765K010.61M9.18M95.74M208.5M242.78M144.7M
Total Liabilities44.86M83.47M100.99M396.29M480.63M520.27M833.04M1.57B1.66B1.74B
Total Debt+25.14M54.79M55.57M316.56M397.04M404.84M612.27M1.18B1.2B1.31B
Net Debt-257.74M-107.8M-325.6M-178.51M-90.39M-127.91M-104.51M103.83M721.62M759.09M
Debt / Equity0.08x0.35x0.15x1.52x1.52x1.47x1.49x13.39x-4.60x
Debt / EBITDA----------
Net Debt / EBITDA----------
Interest Coverage-40.67x-49.57x-31.89x-12.07x-8.49x-8.97x-9.27x-17.29x-8.69x-10.34x
Total Equity+311.7M154.48M361.06M208.27M261.67M275.88M410.47M87.95M-331.92M285.38M
Equity Growth %0.67%-0.5%1.34%-0.42%0.26%0.05%0.49%-0.79%-4.77%1.86%
Book Value per Share5.322.505.422.713.092.833.660.71-2.361.74
Total Shareholders' Equity311.7M154.48M361.06M208.27M261.67M275.88M410.47M87.95M-331.92M285.38M
Common Stock618K620K766K773K897K1.03M1.19M1.36M1.48M1.79M
Retained Earnings-588.96M-765.24M-957.88M-1.28B-1.54B-1.83B-2.27B-2.7B-3.45B-4.36B
Treasury Stock0000000000
Accumulated OCI-5.31M-65K-3K-9K-10K193K968K756K-745K-2.29M
Minority Interest0000000000

Cash Flow

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-100.7M-146.71M-159.62M-257.98M-250.65M-219.35M-363.3M-400.44M-536.25M-683.88M
Operating CF Margin %----26.23%-1.84%-1.33%-1.93%-1.63%-1.76%-1.88%
Operating CF Growth %-0.56%-0.46%-0.09%-0.62%0.03%0.12%-0.66%-0.1%-0.34%-0.28%
Net Income-118.18M-176.27M-192.65M-324.28M-254.34M-294.09M-434.65M-481.53M-749.57M-913.77M
Depreciation & Amortization1.98M2.44M2.9M4.83M10.18M14.15M14.18M10.33M10.58M11.01M
Stock-Based Compensation15.59M18.04M18.07M26.24M26.97M36.16M46.02M57.69M74.78M96.83M
Deferred Taxes0002.21M0017.69M000
Other Non-Cash Items534K452K776K17.29M29.5M27.39M52.04M6.5M167.18M125.22M
Working Capital Changes-623K8.64M11.28M15.74M-62.97M-2.95M-58.58M6.58M-39.22M-3.18M
Change in Receivables000-5.51M-13.72M2.67M-8.12M-6.42M-11.96M-12.93M
Change in Inventory000-7.03M-21.28M-21.18M-17.46M-1.71M-13.61M-17.04M
Change in Payables-1.78M2.77M3.6M3.87M-4.97M29.82M-7.58M50.01M15.15M44.59M
Cash from Investing+-3.45M-4.2M-3M-14.81M-42.27M-6.82M-64.28M-34.58M-223.6M-583.17M
Capital Expenditures-3.45M-4.2M-3M-14.81M-42.27M-6.82M-7.29M-9.88M-13.29M-21.92M
CapEx % of Revenue---1.51%0.31%0.04%0.04%0.04%0.04%0.06%
Acquisitions----------
Investments----------
Other Investing000000-57M-24.71M00
Cash from Financing+227.8M30.67M381.09M386.74M285.28M271M612.55M793.27M168.44M1.34B
Debt Issued (Net)----------
Equity Issued (Net)----------
Dividends Paid0000000000
Share Repurchases----------
Other Financing4.86M-411K3.43M-14.24M24.2M25.14M6.32M151.72M17.18M109.51M
Net Change in Cash----------
Free Cash Flow+-104.15M-150.91M-162.62M-272.79M-292.92M-226.17M-370.59M-410.32M-549.53M-705.8M
FCF Margin %----27.74%-2.15%-1.38%-1.97%-1.67%-1.8%-1.94%
FCF Growth %-0.49%-0.45%-0.08%-0.68%-0.07%0.23%-0.64%-0.11%-0.34%-0.28%
FCF per Share-1.78-2.44-2.44-3.55-3.46-2.32-3.31-3.33-3.91-4.30
FCF Conversion (FCF/Net Income)0.85x0.83x0.83x0.80x0.99x0.75x0.84x0.83x0.72x0.75x
Interest Paid03.61M5.17M6.29M7.88M9.19M10.89M10.16M35.79M40.57M
Taxes Paid085K166K154K339K814K1.56M1.72M1.96M2.5M

Key Ratios

Metric2015201620172018201920202021202220232024
Return on Equity (ROE)-47.47%-75.62%-74.74%-113.92%-108.24%-109.42%-126.66%-193.22%--320.2%
Return on Invested Capital (ROIC)-166.53%-258.43%-344.98%-706.93%-175.53%-124.62%-123.95%-137.82%-183.06%-91.86%
Gross Margin---75.36%82.26%75.75%76.57%77.53%78.52%76.43%
Net Margin----3297.17%-186.37%-178.87%-230.63%-196.26%-245.59%-251.24%
Debt / Equity0.08x0.35x0.15x1.52x1.52x1.47x1.49x13.39x-4.60x
Interest Coverage-40.67x-49.57x-31.89x-12.07x-8.49x-8.97x-9.27x-17.29x-8.69x-10.34x
FCF Conversion0.85x0.83x0.83x0.80x0.99x0.75x0.84x0.83x0.72x0.75x
Revenue Growth-100%---1287.56%20.48%14.63%30.19%24.39%19.17%

Revenue by Segment

2021202220232024
Reportable---363.71M
Reportable Growth----

Revenue by Geography

2021202220232024
UNITED STATES159.51M185.99M224.19M254.8M
UNITED STATES Growth-16.60%20.54%13.65%
JAPAN16.01M56.51M65.73M87.7M
JAPAN Growth-253.03%16.33%33.42%
Europe And The Rest Of The World12.95M2.86M15.28M21.21M
Europe And The Rest Of The World Growth--77.92%434.64%38.80%

Frequently Asked Questions

Growth & Financials

Insmed Incorporated (INSM) reported $447.0M in revenue for fiscal year 2024. This represents a 10020% increase from $4.4M in 2011.

Insmed Incorporated (INSM) grew revenue by 19.2% over the past year. This is strong growth.

Insmed Incorporated (INSM) reported a net loss of $1.18B for fiscal year 2024.

Dividend & Returns

Insmed Incorporated (INSM) has a return on equity (ROE) of -320.2%. Negative ROE indicates the company is unprofitable.

Insmed Incorporated (INSM) had negative free cash flow of $906.1M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.